H eart failure (HF) is a prevalent condition in the United States, affecting 5.8 million patients, 1 and is associated with high hospitalization and readmission rates, mortality, and cost of care. [1] [2] [3] [4] [5] [6] For patients with HF, discontinuities and lack of post-acute care monitoring can increase overall health care resource use through readmissions or worsened morbidity. 7, 8 Persistently high readmission rates for patients with HF suggest that further improvements to existing care transition approaches are needed, 1, 9 as evidenced by the readmission-related financial penalties of approximately $428 million affecting 2610 hospitals in the third year of the Centers for Medicare & Medicaid Services Hospital Readmission Reduction Program.
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Interventions to improve the care transition process have been shown to reduce readmissions while potentially improving morbidity and mortality in randomized clinical trials (RCTs), [11] [12] [13] [14] particularly for patients with HF. 15 However, many of these interventions were tested in single centers with limited numbers of patients. Moreover, sustainability of researchderived care transition approaches is difficult, with many requiring intensive in-person interactions that are not always acceptable to patients 16, 17 and incurring costs to health professional organizations that may not be favorable under current health care financing arrangements. 18 Telehealth technology, including mobile health and remote patient monitoring technologies, potentially provides more cost-effective solutions to the problems of financial viability and home visit acceptability by substituting for in-person interactions. However, its effectiveness to date (particularly in patients with HF) has been mixed. The largest RCT in the United States to date in this area, Telemonitoring to Improve Heart Failure Outcomes, did not show any significant benefit from its telehealth approach, 19 perhaps because of the type of technology used, low adherence rates, lack of patient engagement before discharge, or handling of values that exceeded threshold variables. 19, 20 Another large RCT in Europe with high adherence rates and improved technology also showed no significant benefit. 21 However, systematic reviews that include these studies continue to suggest significant reductions in mortality, morbidity, and HF-related hospitalizations.
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The objective of the Better Effectiveness After TransitionHeart Failure (BEAT-HF) study was to evaluate the effectiveness of a care transition intervention using remote patient monitoring in reducing 180-day all-cause readmissions among a broad population of older adults hospitalized with HF. It was designed to address issues identified with the Telemonitoring to Improve Heart Failure Outcomes RCT, including using newer remote monitoring approaches, engaging patients before discharge, and pairing remote monitoring with a telephone-based nurse care manager via scheduled contacts similar to in-person care transition programs.
Methods

Study Design
The BEAT-HF study was a prospective, 2-arm (with a 1:1 randomization) multicenter RCT conducted at 6 academic medical centers in California to compare usual care with a telehealthbased care transition intervention for older patients who are discharged home after inpatient treatment for decompensated HF. 25 Five of the sites are part of the University of California system, including the University of California in Davis, Irvine, Los Angeles, San Diego, and San Francisco. The sixth location is Cedars-Sinai Medical Center in Los Angeles, which has a mixed-model medical staff that includes full-time faculty, a multispecialty group practice, and many independent private physicians. Three of the sites are major heart transplant centers, and an additional 3 serve as safety-net hospitals for their respective regions. Block randomization was conducted within each site using random blocks of 4 to 8 individuals via a web-based, computerized, random number generator. The study was approved by the University of California, Los Angeles (UCLA) institutional review board, and all other study institutions were subject to the UCLA institutional review board review. A data and safety monitoring board was convened for the study and reviewed data during the study enrollment period. The study was registered at clinicaltrials.gov (NCT01360203). The full study protocol can be found in the Supplement.
Patient Population
Individuals admitted as hospital inpatients or on observation status were eligible if they were 50 years or older, were receiving active treatment for decompensated HF (defined as HF with the initiation of or an increase in diuretic treatment), were expected to be discharged to their home, and were capable of providing written informed consent in English, Spanish, Farsi, or Russian. Enrollment criteria were expanded in January 2012 to include all patients being actively treated for HF instead of just those having a principal diagnosis of HF. This change was made because patients deemed prospectively as not having a principal diagnosis of HF were being coded as patients with HF after their discharge because of patients with multiple active problems. The study exclusions can be grouped into 3 main categories. 25 First were patients who did not have the cognitive or physical ability (eg, dementia or weight >204 kg) or access to resources (eg, working telephone or usual source of care) required to participate fully in the BEAT-HF intervention. Second were patients already in a system of care providing more health professional contacts than the planned intervention (eg, living in a skilled nursing facility, receiving chronic hemodialysis, or awaiting or having received an organ transplant). Third were patients whose HF was due to a cardiovascular condition that was expected to improve because of medical intervention (eg, percutaneous coronary intervention or interventional valve procedure during hospitalization).
Intervention
The intervention consisted of the following 3 components conducted by registered nurses: predischarge HF education, regularly scheduled telephone coaching, and home telemonitoring of weight, blood pressure, heart rate, and symptoms. 25 The predischarge health education was conducted by a study nurse who was not part of the usual care team. The nurse guided pa-method to ensure patient understanding. 27,28 The predischarge education also included a demonstration of how to use the remote home telemonitoring equipment and an explanation of why monitoring physiological variables is important for patients. The electronic equipment (Bluetooth enabled; Bluetooth SIG, Inc) consisted of a wireless transmission pod, a weight scale, and a blood pressure and heart rate monitor integrated with a device that could display text questions and send simple text responses. Devices automatically transmitted data back to central servers for telemonitoring review by telephone call center study nurses based at the primary study site.
Intervention patients were scheduled to receive 9 telephone coaching calls over a 6-month period, generally from the same call center nurse, who had access to patients' medical histories and medication records. The nurse first contacted each enrolled patient 2 or 3 days after discharge from the hospital to reinforce the predischarge health coaching topics. Subsequent telephone nurse coaching then occurred on a weekly basis during the first month after discharge. After the first month, nurse coaching telephone calls were made monthly until the end of the 6-month study period. All telephone calls covered content reinforcing the predischarge education materials. Intervention patients were asked to use the telemonitoring equipment daily to transmit their weight, blood pressure, heart rate, and responses to 3 symptom questions, which were sent via cellular bandwidth to a secure server and were accessed daily by the telephone call center nurses. Readings that exceeded predetermined threshold variables generated a trigger for the telephone call center nurse to telephone the patient to investigate potential causes. When symptoms were concerning, patients were encouraged to contact their health professionals, although these individuals were also notified by the telephone call center nurses. If deemed necessary, the telephone call center nurses advised patients to call 911 or go to their nearest hospital emergency department. Telephone call center nurses also called patients who had stopped transmitting data to determine the reason and encourage the patient to resume daily monitoring.
Usual care at the sites included robust predischarge education and often a postdischarge follow-up telephone call.
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No additional surveillance was provided to control patients beyond whatever may have been requested as part of routine clinical practice, and the intervention did not substitute for usual care surveillance. Patients were not precluded from exposure to other readmission reduction or chronic disease management programs implemented by hospitals, physician groups, or health plans, such as education about HF, pharmacist consultation, and postdischarge telephone calls.
For all participants, enrollment nurses conducted baseline surveys via in-person interviews before randomization. On completion, patients were randomized via the web-based enrollment software, with randomization notification provided by the enrollment nurse. All participants were contacted for survey interviews at 7 days, 30 days, and 180 days after discharge by staff at the coordinating center who were unaware of the treatment randomizations. During these telephone interviews, information was collected about quality of life, satisfaction with care, and use of medications. 
Outcome Measures
The primary outcome measure was 180-day all-cause readmission. Secondary outcomes reported herein include 30-day all-cause readmission, 30-day mortality, and 180-day mortality. 25 Readmissions were identified from participating sites' hospitalization data, combined with California's inpatient discharge data for hospitalizations at nonstudy sites obtained from the California Department of Public Health Office of Statewide Health Planning and Development. Mortality was assessed using the Social Security and National Death Index, hospital data systems, contact with family members, and searches of obituaries. 30 Quality of life was measured using the Minnesota Living With Heart Failure Questionnaire conducted via computer-assisted telephone interview.
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Statistical Analysis
Our sample size provided 80% power to detect a relative reduction of 28% in the primary outcome of 180-day readmission with a type I error of 0.05 after adjusting for withinhospital clustering. We conducted unadjusted intent-to-treat analyses. Individuals who had fully withdrawn consent were censored on the date of withdrawal in hazard models for the primary outcome and for secondary outcomes related to readmission and mortality. We conducted unadjusted analyses, followed by prespecified multivariable analyses to adjust for patient characteristics that may have been unequally distributed across treatment groups and may have influenced outcomes. These multivariable analyses include logistic regression models for readmission and mortality analyses. Models controlled for age, sex, race/ethnicity, insurance, comorbidities based on the Health Care Utilization Project methods, 6 year and quarter of enrollment, social isolation as measured by the Lubben Social Network Scale score, 31 and income level. Enrollment site was controlled for using random effects. Models also controlled for baseline quality-of-life scores in quality-of-life score analyses. Quality-of-life 30-day and 180-day analyses were only conducted for those individuals who reported quality-of-life data at the analyzed time point. After adjusting for days alive, adherence was measured in each measurement period separately for health coaching telephone calls (as the percentage of protocol-required calls that were completed) and for telemonitoring (as the percentage of days transmitting any type of data using telemonitoring).
Results
We assessed 30 844 individuals between October 12, 2011, and September 30, 2013, for study eligibility (Figure 1) . Of 
Primary Outcome
The overall proportion of study participants who experienced our primary outcome (unadjusted, 180-day all-cause readmission) was 50.0% (718 of 1437) ( Table 3) . There was no significant difference detected in unadjusted (P = . (Figure 2 ). Subgroup analyses for our primary outcome showed no significant differences for those 65 years or older, male or female sex, race/ethnicity categories, or New York Heart Association classification. None of the subgroups showed evidence of meaningful effect modification ( Table 4) .
Secondary Outcomes
Findings for 30-day readmission mirrored those for 180-day readmission. The overall proportion of study participants with 30-day all-cause readmission was 22.7% (162 of 715) ( Table 2 ). There was no significant difference detected in unadjusted (P = .56) or adjusted (P = .63) analyses between the proportion of intervention participants (22.7% [162 of 715]) or usual care participants (21.6% [156 of 722]) with 30-day all-cause readmission. The unadjusted hazard ratio for 30-day all-cause readmission with receipt of the intervention was 1.03 (95% CI, 0.83-1.29; P = .77). The adjusted hazard ratio for 30-day allcause readmission with receipt of the intervention was 1.01 (95% CI, 0.80-1.28; P = .91) (Figure 2) .
The overall proportion of study participants with 30-day all-cause mortality was 4.4% (63 of 1437) ( Table 2) . Nonsignificant differences were detected in unadjusted analysis (P = .06) and significant differences in adjusted analysis (P = .04) between the proportion of intervention participants (3.4% [24 of 715]) or usual care participants (5.4% [39 of 722]) with 30-day all-cause mortality. The unadjusted hazard ratio for 30-day all-cause mortality with receipt of the intervention was 0.61 (95% CI, 0.37-1.02; P = .06), and the adjusted hazard ratio for 30-day all-cause mortality with receipt of the intervention was 0.53 (95% CI, 0.31-0.93; P = .03) (Figure 2) . Review of the timing of deaths indicates that this finding was because of in-hospital death differences after randomization, which would make it less likely to be owing to the intervention.
The overall proportion of study participants with 180-day all-cause mortality was 14.9% (214 of 1437) ( Table 2 ). There was no significant difference detected in unadjusted (P = .34) or adjusted (P = .30) analyses between the proportion of in- Failure Questionnaire 30 has a total score that can range from 0 to 105. A lower score indicates less effect of heart failure on a patient's quality of life. The hazard ratio for 180-day all-cause mortality with receipt of the intervention was 0.88 (95% CI, 0.67-1.15; P = .32), and the adjusted hazard ratio for 180-day all-cause mortality with receipt of the intervention was 0.85 (95% CI, 0.64-1.13; P = .26) (Figure 2) . The overall mean,30-day quality-of-life score was 31.23, and the overall mean, 180-day quality-of-life score was 30.49 (Table 3 ). There was a significant difference in 180-day qualityof-life scores between the intervention participants (mean, 28.50) and the control participants (mean, 32.63) in unadjusted (P = .02) and adjusted (P = .02) analyses.
Discussion
The BEAT-HF study is one of the largest RCTs of remote patient telemonitoring in an HF population. It was designed to determine the effectiveness of the intervention using a broad population of patients hospitalized with HF that would be consistent with actual practice. Similar to other large RCTs of telemonitoring, we did not find significant effects of the BEAT-HF intervention on all-cause readmission within the first 30 or 180 days. The physiological signals of changes in daily weights and increased symptoms may not provide adequate warning of impending decompensation in patients with HF.
20,32 Trials of im- Dashed lines are for the intervention, and solid lines are for usual care. Adjusted hazard ratios, 95% CIs, and P values are from multivariable Cox proportional hazards regression models for readmission and mortality analyses. Models controlled for age, sex, race/ethnicity, insurance, income, social isolation, comorbidities, year, and quarter of enrollment, with enrollment site controlled for as random effects. A and B, The hazard ratio for 30-day readmission with the intervention is 1.03 (95% CI, 0.83-1.29; P = .77). The adjusted hazard ratio for 30-day readmission with the intervention is 1.01 (95% CI, 0.80-1.28; P = .91).
The hazard ratio for 180-day readmission with the intervention is 1.03 (95% CI, 0.89-1.19; P = .73). The adjusted hazard ratio for 180-day readmission with the intervention is 1.03 (95% CI, 0.88-1.20; P = .74). C and D, The hazard ratio for 30-day mortality with the intervention is 0.61 (95% CI, 0.37-1.02; P = .06). The adjusted hazard ratio for 30-day mortality with the intervention is 0.53 (95% CI, 0.31-0.93; P = .03). The hazard ratio for 180-day mortality with the intervention is 0.88 (95% CI, 0.67-1.15; P = .32). The adjusted hazard ratio for 180-day mortality with the intervention is 0.85 (95% CI, 0.64-1.13; P = .26).
ingly recognized as a complex phenomenon, the cause of which is not solely limited to physiological variables. 34 In addition, all participating sites were already focused on readmissions among patients with HF because of impending potential penalties from the Hospital Readmission Reduction Program and had implemented readmission reduction efforts. 29 Similar types of interventions potentially could show effects among patients who have not previously been the focus of readmission reduction efforts. Although the primary and secondary readmission outcome measures were not met, we found that the BEAT-HF intervention had significant effects on adjusted analyses of the prespecified secondary outcome measure of 30-day mortality. However, review of deaths suggests that this finding was a result of in-hospital death differences after randomization, which would make it less likely to be due to the intervention.
We also found that the BEAT-HF intervention had significant effects on quality of life among 180-day survey respondents. Findings for quality of life are limited by survey response rates. Although these rates were stable between 30 days and 180 days after accounting for mortality, survey nonrespondents differed in baseline characteristics from survey respondents and potentially could have different quality-oflife outcomes. Further study would be required to validate this finding because the BEAT-HF trial was not specifically designed or powered for this outcome.
The BEAT-HF study had several limitations. Because the major source of the BEAT-HF funding was derived from American Recovery and Reinvestment Act of 2009 funds, we could not extend enrollment beyond September 30, 2013. Doing so may have strengthened the 30-day mortality findings because the study was not powered for this specific outcome. The study sites are all academic medical centers in California, which could limit generalizability. However, half of the sites included safety-net hospitals, and the broad patient eligibility criteria increase generalizability. The use of other types of personnel instead of registered nurses potentially could have affected study outcomes. The intervention was not directly integrated with the physician practices caring for the patients, which is increasingly possible with advances in electronic health records. The effectiveness of transition of care, disease management, and telemonitoring interventions may be highly dependent on how they are integrated and adhered to in practice. 32 Adherence to the BEAT-HF intervention appears to have been a critical factor. Despite deploying several strategies to promote patient engagement and foster adherence with the telemonitoring and telephone call center intervention, only 61.4% (439 of 715) and 55.4% (396 of 715) of patients randomized to the intervention were more than 50% adherent to telephone calls and telemonitoring, respectively, within the first 30 days. Remote patient monitoring has also experienced significant technological change, including increasing use of tablets and other remote sensors. Newer approaches, such as implantable devices, could increase adherence or provide better information to identify problems after discharge.
Conclusions
The BEAT-HF study found that a combination of remote patient monitoring with care transition management did not reduce 180-day all-cause readmission after hospitalization for HF. Hospitalizations in the first 30 days and 180-day mortality were also not reduced with the intervention. Individuals participating in this intervention may experience quality-oflife improvements at 180 days. However, further studies would be needed to confirm these findings. 
